Erytech Pharma SA (NASDAQ:ERYP) was the target of a large decline in short interest in July. As of July 31st, there was short interest totalling 1,700 shares, a decline of 19.0% from the June 30th total of 2,100 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average daily volume of 600 shares, the short-interest ratio is currently 2.8 days.
Several equities analysts have recently weighed in on ERYP shares. Zacks Investment Research upgraded Erytech Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, July 10th. ValuEngine upgraded Erytech Pharma from a “sell” rating to a “hold” rating in a report on Tuesday, July 2nd.
Shares of NASDAQ:ERYP remained flat at $$5.71 during trading on Tuesday. The stock had a trading volume of 100 shares, compared to its average volume of 407. Erytech Pharma has a fifty-two week low of $5.30 and a fifty-two week high of $10.71. The company has a current ratio of 7.26, a quick ratio of 7.19 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $102.51 million, a price-to-earnings ratio of 2.34 and a beta of 1.49. The company’s 50 day moving average price is $6.47.
ERYTECH Pharma SA, a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia.
Featured Story: How to find the components of the quick ratio
Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.